TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16041191

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin 5000 U subcutaneously (s.q.) twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin 5000 U subcutaneously (s.q.) three times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins
Number of subjects: 0
Study: 12446055

Group type: EXPERIMENTAL
Intervention: FDG PET imaging before revascularization
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Combination of PET and clinical parameters
Number of subjects: 82
Study: 10336532

Group type: EXPERIMENTAL
Intervention: Ibuprofen (2400 mg p.o.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8938155

Group type: EXPERIMENTAL
Intervention: HBIg immunoprophylaxis (10,000 IU monthly)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No specific therapy
Number of subjects: 52
Study: 1927823

Group type: EXPERIMENTAL
Intervention: Coronal phase‐contrast MR angiography
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Time‐of‐flight MR angiography
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combined axial and coronal phase‐contrast images
Number of subjects: 33
Study: 6824558

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desmethylmianserin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8-hydroxymianserin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mianserin-N-oxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mianserin (racemate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desmethylmianserin and 8-hydroxymianserin
Number of subjects: 0
Study: 30798010

Group type: EXPERIMENTAL
Intervention: dlPFC group (n = 17)
Number of subjects: 38

Group type: COMPARATOR
Intervention: VC/control group (n = 21)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study: 30340765

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg BID
Number of subjects: 1694

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg BID
Number of subjects: 1694

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1694
Study: 27048437

Group type: EXPERIMENTAL
Intervention: vBloc therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 84
Study: 25254898

Group type: EXPERIMENTAL
Intervention: Bulgarian squat on stable surface
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bulgarian squat on unstable surface
Number of subjects: 15

Group type: COMPARATOR
Intervention: Regular squat on stable surface
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Unstable surfaces
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bulgarian squat and regular squat
Number of subjects: 15
Study: 22366365

Group type: EXPERIMENTAL
Intervention: Hyaluronate injection (once a week for 3 weeks)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Corticosteroid injection (once)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Hyaluronate injection
Number of subjects: 105

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 105
Study: 20736504

Group type: EXPERIMENTAL
Intervention: Patients with LVH
Number of subjects: 3201

Group type: COMPARATOR
Intervention: Patients without LVH
Number of subjects: 3201

Group type: COMPARATOR
Intervention: CKD patients without LVH
Number of subjects: 3201

Group type: EXPERIMENTAL
Intervention: CKD patients with LVH
Number of subjects: 3201

Group type: EXPERIMENTAL
Intervention: Patients without CKD but with LVH
Number of subjects: 3201

Group type: COMPARATOR
Intervention: Patients without CKD or LVH
Number of subjects: 3201
Study: 17372796

Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention for smoking cessation counseling
Number of subjects: 588

Group type: COMPARATOR
Intervention: Control group (no tailored intervention)
Number of subjects: 588
Study: 15737299

Group type: EXPERIMENTAL
Intervention: Education program and clinical decision support system (CDSS) based on GINA recommendations
Number of subjects: 198

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 198
Study: 11891668

Group type: EXPERIMENTAL
Intervention: Diltiazem slow releasing formulation (90 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Diltiazem moderate releasing formulation (90 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Diltiazem fast releasing formulation (90 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Diltiazem oral solution (90 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Dissolution method using USP Apparatus II with purified water
Number of subjects: 7
Study: 9865999

Group type: EXPERIMENTAL
Intervention: TCu 380A IUD
Number of subjects: 1396

Group type: COMPARATOR
Intervention: ML 250 IUD
Number of subjects: 1396
Study: 8588962

Group type: EXPERIMENTAL
Intervention: Biodegradable implants (self‐reinforced poly‐L‐lactide wire combined with self‐reinforced polyglycolide screw or self‐reinforced poly‐L‐lactide plug)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Metallic implants (tension band wiring, Kirschner wire and metallic cerclage wire)
Number of subjects: 35
Study: 2577748

Group type: EXPERIMENTAL
Intervention: Pirprofen (Rengasil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piritramide (Dipidolor)
Number of subjects: 0
Study: 787015

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study: 30467071

Group type: EXPERIMENTAL
Intervention: High fat diet (Diet HF)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Low fat diet (Diet LF)
Number of subjects: 282
Study: 28390502

Group type: EXPERIMENTAL
Intervention: Co‐ruminative style
Number of subjects: 0

Group type: COMPARATOR
Intervention: Problem‐solving style
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distracting style
Number of subjects: 0
Study: 26022314

Group type: EXPERIMENTAL
Intervention: sTNF-R1, CRP, and age
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Baseline analytes
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Individual biomarkers
Number of subjects: 39
Study: 23707271

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21775106

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 156 mg
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 234 mg
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 19467177

Group type: EXPERIMENTAL
Intervention: Omalizumab (minimum, 0.016 mg/kg per IgE IU/mL every 4 weeks)
Number of subjects: 811

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 811
Study: 16924047

Group type: EXPERIMENTAL
Intervention: Intense pulsed light treatments (3 treatments at 1-month intervals)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 32
Study: 15570138

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 256

Group type: COMPARATOR
Intervention: Exercise stretching control
Number of subjects: 256
Study: 11230588

Group type: EXPERIMENTAL
Intervention: TRH treatment
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Cortisol levels (measured at various time points)
Number of subjects: 314
Study: 9121357

Group type: EXPERIMENTAL
Intervention: Tolterodine 1 or 2 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PNU‐200577 (active metabolite of Tolterodine)
Number of subjects: 0
Study: 8435030

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 1126
Study: 3300426

Group type: EXPERIMENTAL
Intervention: isoflurane in nitrous oxide and oxygen
Number of subjects: 110

Group type: COMPARATOR
Intervention: isoflurane in air and oxygen
Number of subjects: 110
Study: 30630795

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin calcium (subcutaneous injection for 5 days)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no anti-coagulant agent)
Number of subjects: 180
Study: 27272517

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (830 nm wavelength, power 150 mW, spot size 1 cm², 30 s per cm², energy density 4.5 J/cm²)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Sham therapy (placebo)
Number of subjects: 123
Study: 26290002

Group type: EXPERIMENTAL
Intervention: Behavior Change Technique Taxonomy version 1 (BCTTv1)
Number of subjects: 40
Study: 23362338

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program (MBSR)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Nutrition education intervention (NEP)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 172
Study: 20197284

Group type: EXPERIMENTAL
Intervention: Low GDP fluid (Gambrosol trio)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard PD fluid
Number of subjects: 80
Study: 18676330

Group type: EXPERIMENTAL
Intervention: Temsirolimus, administered at a flat weekly IV dose of 25 mg over 30-60 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-alpha (standard therapy)
Number of subjects: 0
Study: 16229958

Group type: EXPERIMENTAL
Intervention: Initial substance use
Number of subjects: 2453

Group type: EXPERIMENTAL
Intervention: Initial number of substance using friends
Number of subjects: 2453

Group type: EXPERIMENTAL
Intervention: Peer substance use
Number of subjects: 2453

Group type: EXPERIMENTAL
Intervention: Adolescent substance use
Number of subjects: 2453
Study: 12505817

Group type: EXPERIMENTAL
Intervention: 1 g of E-EPA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10836215

Group type: EXPERIMENTAL
Intervention: Simultaneous continuous ante/retrograde cardioplegia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Retrograde continuous blood cardioplegia
Number of subjects: 40
Study: 8801700

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Non-compliance
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low S-citalopram due to carbamazepine treatment
Number of subjects: 44
Study: 1353282

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lung surfactant (prepared from pigs)
Number of subjects: 0
Study: 6377873

Group type: EXPERIMENTAL
Intervention: Cranial radiation therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: No cranial radiation therapy (Control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Entire sample (with and without cranial radiation)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Parental education levels
Number of subjects: 18
Study: 31411338

Group type: EXPERIMENTAL
Intervention: Educational sessions led by a lay-tutor (former patient) in conjunction with physiotherapists; 10-week programme comprising 10 hours of education and 20 hours of physical exercise.
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group led by 2 physiotherapists for the entire educational programme; 10-week programme comprising 10 hours of education and 20 hours of physical exercise.
Number of subjects: 87
Study: 30559886

Group type: COMPARATOR
Intervention: Micro‐Osteoperforations (MOPs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low‐Level Laser Therapy (LLLT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combination of MOPs and LLLT
Number of subjects: 30
Study: 27738237

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study: 25013370

Group type: EXPERIMENTAL
Intervention: Benidipine (4.8 mg/day)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (8.2 mg/day)
Number of subjects: 346
Study: 22665131

Group type: EXPERIMENTAL
Intervention: Beeswax and herbal oil cream
Number of subjects: 52

Group type: COMPARATOR
Intervention: Aqueous cream
Number of subjects: 52
Study: 19483369

Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT) program with monthly 30-min sessions for 6 months
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT) program (per-protocol analysis)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT) program (subgroup analysis for low job control)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT) program (subgroup analysis for high job control)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 149
Study: 18260374

Group type: EXPERIMENTAL
Intervention: Inhalation of pulmicort 2 ml plus 0.5% Aeuromycin solution 10 ml by oxygen driving force, once a day for 3 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rhinocort
Number of subjects: 60
Study: 16127560

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy with absolute alcohol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Banding ligation
Number of subjects: 46
Study: 12399699

Group type: EXPERIMENTAL
Intervention: Cervitec varnish applied to one tooth at baseline and after 3 and 6 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control tooth (no varnish applied)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cervitec varnish
Number of subjects: 16
Study: 9952020

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Complement activation fragments (C4d, Bb, iC3b, SC5b‐9) measured via ELISA
Number of subjects: 2
Study: 7587848

Group type: EXPERIMENTAL
Intervention: Alprazolam (up to 2 mg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 2245970

Group type: EXPERIMENTAL
Intervention: GH replacement therapy, dosage: around 2 IU/m2/day, duration: 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: GH administration to normal subjects
Number of subjects: 0
Study: 35213

Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31470877

Group type: EXPERIMENTAL
Intervention: Collaborative game mode
Number of subjects: 40

Group type: COMPARATOR
Intervention: Competitive game mode
Number of subjects: 40

Group type: COMPARATOR
Intervention: Co-active game mode
Number of subjects: 40
Study: 27635023

Group type: EXPERIMENTAL
Intervention: 90Y‐DOTATOC
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: 177Lu‐DOTATOC
Number of subjects: 1535

Group type: COMPARATOR
Intervention: Radiopeptide therapy (90Y‐DOTATOC or 177Lu‐DOTATOC)
Number of subjects: 1535
Study: 26473561

Group type: EXPERIMENTAL
Intervention: Resilience training combined with cognitive behavioral and solution-focused counseling
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 82
Study: 24220602

Group type: EXPERIMENTAL
Intervention: Automated software system for identifying patients eligible for OAC therapy and increasing uptake, used in 23 intervention practices for 6 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care in 23 control practices.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated software system for identifying patients eligible for OAC therapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care in control practices.
Number of subjects: 0
Study: 21507688

Group type: EXPERIMENTAL
Intervention: EndoSequence Bioceramic Root‐end Repair (BCRR) (n = 15)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: White mineral trioxide aggregate (WMTA) (n = 15)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (unfilled specimens, n = 10)
Number of subjects: 40
Study: 19742335

Group type: EXPERIMENTAL
Intervention: Resection of pancreatic capsule and anterior layer of transverse mesocolon (Group R)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (Group N)
Number of subjects: 213
Study: 17719390

Group type: EXPERIMENTAL
Intervention: 20 mL of autologous platelet-poor plasma (PPP) gel
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1-gram of bovine microfibrillar collagen (MFC)
Number of subjects: 24
Study: 15121561

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Continuous combined estrogen plus progestin therapy (2 mg of 17 beta‐estradiol plus 1 mg of norethisterone acetate)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Continuous combined estrogen plus progestin therapy
Number of subjects: 1008
Study: 11346146

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b 3 Million Units thrice weekly (group A)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b 5 Million Units thrice weekly (group B)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b 5 Million Units daily (group C)
Number of subjects: 63
Study: 9876054

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate (250 mg/62 mg t.i.d. or 125 mg/31 mg t.i.d. if aged under 6 years) for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefaclor (250 mg t.i.d. or 125 mg t.i.d. if aged under 6 years) for 7 days
Number of subjects: 0
Study: 7976408

Group type: EXPERIMENTAL
Intervention: Exhausting treadmill running (5.27 m/s for ET and 5.59 m/s for ST) for 1 minute
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Recovery after exhausting exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Non-exhausting bouts of exercise at lower speed or shorter duration
Number of subjects: 11
Study: 2491982

Group type: EXPERIMENTAL
Intervention: Experimental intracervical device (ICD)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Levonorgestrel‐releasing intrauterine device (LNG‐IUD)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Copper Nova‐T IUD
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Adjusted probabilities of discontinuation for ICD
Number of subjects: 253

Group type: COMPARATOR
Intervention: Adjusted probabilities of discontinuation for LNG‐IUD
Number of subjects: 253

Group type: COMPARATOR
Intervention: Adjusted probabilities of discontinuation for Nova‐T
Number of subjects: 253
Study: 5053

Group type: EXPERIMENTAL
Intervention: Buffered cephalothin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cephapirin
Number of subjects: 12
Study: 31760109

Group type: EXPERIMENTAL
Intervention: Integrated psychosocial treatment (Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual care through a Veteran's Administration co‐occurring disorders medical clinic
Number of subjects: 37
Study: 31159277

Group type: COMPARATOR
Intervention: Health Behavioural Intervention
Number of subjects: 0
Study: 27908210

Group type: EXPERIMENTAL
Intervention: Combined hormonal contraceptive (COC) containing 0.020 mg of ethynyl estradiol (EE)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Combined hormonal contraceptive (COC) containing 0.030 mg of ethynyl estradiol (EE)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Natural COC containing 1.5 mg of estradiol (E2)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Vaginal ring releasing 0.015 mg of EE + 0.120 mg of etonogestrel
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Progestin only subcutaneous contraceptive implant releasing etonogestrel
Number of subjects: 556

Group type: COMPARATOR
Intervention: No hormonal contraceptive methods (controls)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Ultrasound evaluation of dorsal clitoral artery
Number of subjects: 556
Study: 25425394

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300U/ml (Gla‐300) administered at a dosage of 0.4U/kg once daily for six days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Insulin glargine 300U/ml (Gla‐300)
Number of subjects: 50
Study: 23778372

Group type: EXPERIMENTAL
Intervention: Usual chiropractic treatment
Number of subjects: 183

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 183
Study: 21060992

Group type: EXPERIMENTAL
Intervention: 3-month course of circuit exercises plus a 3-hour lesson on coping with osteoporosis
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (CT)
Number of subjects: 89
Study: 19261771

Group type: EXPERIMENTAL
Intervention: wP vaccine
Number of subjects: 234

Group type: COMPARATOR
Intervention: wP(low) vaccine
Number of subjects: 234
Study: 16954234

Group type: EXPERIMENTAL
Intervention: Primers amplifying the E2 coding region
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Primers amplifying the 5' nontranslated region and nonstructural protein-coding regions 3 and 5A
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Quantitative GBV-C RNA method
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Subjects with both GBV-C E2 antibody and viremia
Number of subjects: 939
Study: 12612504

Group type: EXPERIMENTAL
Intervention: Pancreatic duct stent placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: No stent (control group)
Number of subjects: 0
Study: 10692622

Group type: EXPERIMENTAL
Intervention: Focused attention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Avoidance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cold pressor pain
Number of subjects: 100
Study: 9354210

Group type: EXPERIMENTAL
Intervention: Pancrease MT4 (8000 unit lipase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancrease MT10 (20,000 units lipase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancrease MT16 (32,000 units lipase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1587874

Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 186

Group type: COMPARATOR
Intervention: Dynamic hip screw
Number of subjects: 186
Study: 3984605

Group type: EXPERIMENTAL
Intervention: Piracetam treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 60